Importantly, this SNP was significantly associated with breast cancer in the overall patient cohort as well as in smaller subgroups based on tumor subtype (ER-positive/PR-positive/Her2-negative and Her2-positive breast cancers), BRCA status (BRCA negative), and age (31-40yrs). This evidence concerns the gene ESR1 and neoplasm.